Humanized anti-S100A9 antibody and uses thereof
US11359010B2 · kind B2 · utility
0Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 11, 2016 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Sep 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.